Trading of Sol-Gel Technologies was halted at 09:45 AM EST due to "LULD pause". Sol-Gel Technologies (SLGL) Competitors $22.67 -3.13 (-12.13%) Closing price 04:00 PM EasternExtended Trading$21.83 -0.84 (-3.71%) As of 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SLGL vs. CHEK, DRCT, SLS, ENTA, LFVN, ACTU, NKTX, NVCT, CYBN, and BIOAShould you be buying Sol-Gel Technologies stock or one of its competitors? The main competitors of Sol-Gel Technologies include Check-Cap (CHEK), Direct Digital (DRCT), SELLAS Life Sciences Group (SLS), Enanta Pharmaceuticals (ENTA), Lifevantage (LFVN), Actuate Therapeutics (ACTU), Nkarta (NKTX), Nuvectis Pharma (NVCT), Cybin (CYBN), and BioAge Labs (BIOA). Sol-Gel Technologies vs. Its Competitors Check-Cap Direct Digital SELLAS Life Sciences Group Enanta Pharmaceuticals Lifevantage Actuate Therapeutics Nkarta Nuvectis Pharma Cybin BioAge Labs Check-Cap (NASDAQ:CHEK) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings. Does the media favor CHEK or SLGL? In the previous week, Sol-Gel Technologies had 4 more articles in the media than Check-Cap. MarketBeat recorded 5 mentions for Sol-Gel Technologies and 1 mentions for Check-Cap. Sol-Gel Technologies' average media sentiment score of 1.24 beat Check-Cap's score of 0.05 indicating that Sol-Gel Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Check-Cap 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sol-Gel Technologies 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CHEK or SLGL more profitable? Check-Cap has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -14.25%. Check-Cap's return on equity of 0.00% beat Sol-Gel Technologies' return on equity.Company Net Margins Return on Equity Return on Assets Check-CapN/A N/A N/A Sol-Gel Technologies -14.25%-11.80%-9.39% Do insiders & institutionals hold more shares of CHEK or SLGL? 1.1% of Check-Cap shares are held by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are held by institutional investors. 0.5% of Check-Cap shares are held by company insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has higher earnings & valuation, CHEK or SLGL? Sol-Gel Technologies has higher revenue and earnings than Check-Cap. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCheck-CapN/AN/A-$17.57M-$3.00-0.21Sol-Gel Technologies$23.93M2.64-$10.58M-$1.23-18.43 Which has more risk and volatility, CHEK or SLGL? Check-Cap has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. SummarySol-Gel Technologies beats Check-Cap on 8 of the 12 factors compared between the two stocks. Get Sol-Gel Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for SLGL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLGL vs. The Competition Export to ExcelMetricSol-Gel TechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$63.16M$4.11B$5.83B$9.73BDividend YieldN/A1.24%3.84%4.09%P/E Ratio-18.4311.2631.1625.99Price / Sales2.6412.23474.86122.97Price / CashN/A6.9837.1558.38Price / Book1.984.929.116.38Net Income-$10.58M-$109.62M$3.26B$265.56M7 Day Performance46.83%5.00%2.06%1.89%1 Month Performance143.50%25.67%5.08%1.23%1 Year Performance226.23%34.52%31.26%21.10% Sol-Gel Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLGLSol-Gel Technologies1.0982 of 5 stars$22.67-12.1%N/A+330.0%$63.16M$23.93M-18.4350News CoveragePositive NewsEarnings ReportGap DownTrading HaltedHigh Trading VolumeCHEKCheck-Cap0.4077 of 5 stars$0.66-0.6%N/A-67.0%$3.89MN/A-0.2280Short Interest ↑DRCTDirect Digital2.5286 of 5 stars$0.40-3.2%$6.00+1,412.5%-87.3%$9.23M$62.29M-0.2260SLSSELLAS Life Sciences Group2.9316 of 5 stars$1.73+6.1%$7.00+304.6%+34.4%$171.63M$1M-5.4110ENTAEnanta Pharmaceuticals3.666 of 5 stars$8.17+2.1%$21.67+165.2%-32.4%$171.02M$64.81M-1.89160LFVNLifevantage3.9835 of 5 stars$13.69+1.5%$30.50+122.8%+48.4%$169.81M$222.35M19.84260News CoveragePositive NewsUpcoming EarningsACTUActuate TherapeuticsN/A$8.25+1.6%$20.50+148.5%-10.9%$166.22MN/A0.0010News CoverageAnalyst RevisionNKTXNkarta2.0708 of 5 stars$2.35+0.9%$13.60+478.7%-56.9%$165.49MN/A-1.59140NVCTNuvectis Pharma3.8378 of 5 stars$6.45+0.3%$15.33+137.7%-11.3%$163.69MN/A-5.518Positive NewsCYBNCybin2.5036 of 5 stars$6.92-2.0%$85.00+1,128.3%N/A$163.24MN/A-1.5850News CoverageAnalyst RevisionBIOABioAge LabsN/A$4.52-0.7%N/AN/A$163.12M$3.86M0.00N/A Related Companies and Tools Related Companies Check-Cap Alternatives Direct Digital Alternatives SELLAS Life Sciences Group Alternatives Enanta Pharmaceuticals Alternatives Lifevantage Alternatives Actuate Therapeutics Alternatives Nkarta Alternatives Nuvectis Pharma Alternatives Cybin Alternatives BioAge Labs Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLGL) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sol-Gel Technologies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sol-Gel Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access